MIH
RNTX

Meitav Investment House’s Rein Therapeutics RNTX Stock Holding History

Meitav Investment House’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,050
Closed -$21K – 426
2021
Q3 		$21K Buy
1,050
+500
+91% +$11K ﹤0.01% 403
2021
Q2 		$14K Hold
550
– – ﹤0.01% 412
2021
Q1 		$16 Buy
+550
New +$18.8K ﹤0.01% 378

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Meitav Investment House's RNTX Position: Q4 2021 in Review

Meitav Investment House sold out of Rein Therapeutics (RNTX) in Q4 2021, closing a stake of 1,050 shares — an estimated $21K sold.

Meitav Investment House first reported a position in RNTX in Q1 2021 and held it in 3 quarters. The position peaked at $21K in Q3 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q4 2021.

  • Meitav Investment House reported no remaining Rein Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Meitav Investment House sold 1,050 Rein Therapeutics shares in Q4 2021, an estimated $21K.
  • Meitav Investment House first reported a position in Rein Therapeutics in Q1 2021 and held it in 3 quarters.
  • Meitav Investment House's Rein Therapeutics position peaked at $21K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2021.

Based on Meitav Investment House's 13F filing for Q4 2021, filed 8 Feb 2022.